PETER REISFELD, M.D.
Dermatology Physician in EAST MEADOW, New York. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
PETER REISFELD, M.D. reported a CMS MIPS final score of 0/100 — below the 83.1 national average — and filed 513 Medicare Part D claims in 2023.
- 0/100
- MIPS score · -83 vs avg
- 513
- Part D claims, 2023
- 91%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
PETER REISFELD, M.D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
0 0th percentile higher than 0% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
PETER REISFELD, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about PETER REISFELD, M.D.?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in New York
How Dermatology Physician compares to other specialties among New York providers
Dermatology Physician share within New York
Dermatology Physician is one of the more visible NUCC categories in New York
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
PETER REISFELD, M.D.'s 2023 MIPS final score plotted against the Dermatology Physician national average
- MIPS Final Score
- 0/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Dermatology Physician) — 0/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Specialty volume Dermatology Physician US NPIs
0/100 MIPS final score — 83.1 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Dermatology Physician. Quality dim: 0.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
PETER REISFELD, M.D. appears in the CMS NPPES registry as a Dermatology Physician provider holding M.D. credentials at 2201 HEMPSTEAD TPKE, EAST MEADOW, NY, 11554, with a listed phone of (516) 572-6501. NPI 1194743286 was issued on 07/17/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what REISFELD most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 513 prescription claims written by this provider, covering 169 Medicare beneficiaries and totaling roughly $67K in drug spend, split 9% brand-name and 91% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 0/100 for the 2023 performance year (Quality 0), compared with the national average of 83.1.
Dermatology Physician is a mid-sized specialty nationwide, with 14,610 enrolled providers across 53 states and an average of 729 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1194743286 |
|---|---|
| Specialty | Dermatology Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 07/17/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm PETER REISFELD, M.D.'s current license status, disciplinary history, and board certifications with the New York State Education Department, Office of the Professions in New York before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Individual
License & disciplinary context — New York NYSBPMC 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 — they are NOT specific to PETER REISFELD, M.D.. To verify PETER REISFELD, M.D.'s current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Generic-heavy
9% brand-name claims vs 91% generic, on 513 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 600
- Total Day Supply
- 13,992
- Brand vs Generic
- 9% brand / 91% generic
- Brand Drug Cost
- $55K
- Generic Drug Cost
- $12K
Patient Demographics
- Average Patient Age
- 77.6 years
- Avg HCC Risk Score
- 1.08
- Gender Split
- 44% female / 56% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What PETER REISFELD, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Triamcinolone Acet…
Triamcinolone Acetonide
69 claims
- Doxycycline Hyclate
Doxycycline Hyclate
56 claims
- Mometasone Furoate
Mometasone Furoate
56 claims
- Hydrocortisone
Hydrocortisone
46 claims
- Mupirocin
Mupirocin
38 claims
- Clobetasol Propion…
Clobetasol Propionate
35 claims
- Ketoconazole
Ketoconazole
34 claims
- Betamethasone Dipr… 23
Betamethasone Diprop Augmented
23 claims
| Drug | Claims |
|---|---|
| Triamcinolone Acetonide | 69 |
| Doxycycline Hyclate | 56 |
| Mometasone Furoate | 56 |
| Hydrocortisone | 46 |
| Mupirocin | 38 |
| Clobetasol Propionate | 35 |
| Ketoconazole | 34 |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 23 |
| Alclometasone Dipropionate | 14 |
| Fluticasone Propionate | 11 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Dermatology Physician Overview
How PETER REISFELD, M.D. fits within the Dermatology Physician landscape nationally.
PETER REISFELD, M.D.'s 513 claims are below the specialty average of 729.
Nearby Dermatology Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as REISFELD.
Compare Dermatology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore New York
Frequently Asked Questions
What is PETER REISFELD, M.D.'s specialty? ▼
How much does PETER REISFELD, M.D. prescribe under Medicare Part D? ▼
What is PETER REISFELD, M.D.'s Medicare quality score? ▼
Where is PETER REISFELD, M.D. located? ▼
What is PETER REISFELD, M.D.'s NPI number? ▼
Does PETER REISFELD, M.D. prescribe more brand-name or generic drugs? ▼
How many Dermatology Physician providers are there in the US? ▼
What drugs does PETER REISFELD, M.D. prescribe most often? ▼
Does PETER REISFELD, M.D. accept Medicare? ▼
How can I verify PETER REISFELD, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology